Topics

Identifying FL11 subtype by characterizing tumor immune microenvironment in prostate adenocarcinoma via Chou's 5-steps rule.

08:00 EDT 28th August 2019 | BioPortfolio

Summary of "Identifying FL11 subtype by characterizing tumor immune microenvironment in prostate adenocarcinoma via Chou's 5-steps rule."

Prostate cancer is one of the leading causes of death in men worldwide, revealing a substantial heterogeneity in terms of molecular and clinical behaviors. Tumor infiltrating immune cell is associated with prognosis and response to immunotherapy in several cancer types. However, until now, the immune infiltrate profile of distinct subtypes for prostate cancer remains poorly characterized. In this study, using immune infiltration profiles as well as transcriptomic datasets, we characterized this subtype of prostate tumors. We observed that the FLI1 subtype of prostate tumors was highly enriched in immune system processes, immune related KEGG pathways and biological processes. We also expanded this approach to explore the immune infiltration profile of the high FLI1 expression subtype for skin cutaneous melanoma, similar results were found. Investigation of the association of immune infiltration features with the FLI1 expression demonstrated that many important features were associated with the FLI1 expression.

Affiliation

Journal Details

This article was published in the following journal.

Name: Genomics
ISSN: 1089-8646
Pages:

Links

DeepDyve research library

PubMed Articles [15634 Associated PubMed Articles listed on BioPortfolio]

An IL-2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune response.

Recent success with immune-checkpoint inhibitors in some tumor types has highlighted the power of the immune system to control and eradicate human cancer cells. However, these therapies have demonstr...

Reshaping Prostate Tumor Microenvironment to Suppress Metastasis via Cancer-Associated Fibroblasts Inactivation with Peptide-Assembly Based Nanosystem.

Prostate cancer is one of the most common malignant tumors in men, and inhibiting metastasis is a key event but still a major challenge in prostate cancer treatment. Cancer-associated fibroblasts (CAF...

Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.

Chemotherapy with Docetaxel (Doc) is efficient in a subset of prostate cancer (PCa) cases; however, most patients ultimately develop resistance to Docetaxel. The tumor immune microenvironment and secr...

PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.

Accumulating evidence shows that tumor cell-specific genomic changes can influence the cross talk between cancer cells and the surrounding tumor microenvironment (TME). Loss of the PTEN tumor suppress...

A Positive Step toward Understanding Double-Negative Metastatic Prostate Cancer.

In this issue of Cancer Cell, Su et al. demonstrate that epigenetic reprogramming by Polycomb Repressive Complex 1 (PRC1) promotes an inflammatory tumor microenvironment in a subtype of metastatic pr...

Clinical Trials [12925 Associated Clinical Trials listed on BioPortfolio]

Analysis of Tumor Mutations and Tumor Microenvironment Using Archival Paraffin-embedded Tumor Specimens

Genomic alterations have long been recognized as an important factor in tumor formation and drive tumor cell growth. However, the degree of genomic mutation (tumor mutation load, TMB) vari...

Investigating and Characterizing the Immune Response to Prostate Cancer

This study is a clinical study to investigate and characterize the immune response profile to four different prostate cancer treatments (total cryotherapy, focal cryotherapy, Cyberknife SB...

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1).

Background: - PD-1/PD-L1 signaling appears to be a major inhibitor of activated T cell anti-tumor immune responses. The rapid, deep and durable responses seen in various malignanc...

The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance

The aim of this study is to evaluate the insulin-like growth factor (IGF) axis involvement in the immune tumor microenvironment in ovarian cancer.

Trial of PalloV-CC in Colon Cancer

This study is a phase Ib prospective, open label study evaluating the effect of vaccination on the immune microenvironment of cancers with results compared to banked tissue from historical...

Medical and Biotech [MESH] Definitions

A tumor necrosis factor receptor subtype that is expressed primarily in IMMUNE SYSTEM cells. It has specificity for membrane-bound form of TUMOR NECROSIS FACTORS and mediates intracellular-signaling through TNF RECEPTOR ASSOCIATED FACTORS.

A B7 antigen subtype that inhibits the costimulation of T-cell activation, proliferation, cytokine production and development of cytotoxicity. The over expression of this protein in a variety of tumor cell types suggests its role in TUMOR IMMUNE EVASION.

GENETIC PHENOMENA characterizing IMMUNITY and the immune response.

Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

Quick Search


DeepDyve research library

Relevant Topic

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...


Searches Linking to this Article